EGFR and glioblastoma: Research conducted in Mischel's laboratory unveiled that resistance to epidermal growth factor receptor (EGFR) inhibitors in glioblastoma could be attributed to the reversible loss of EGFRvIII gain-of-function mutations on eccDNA.21